Intellia Therapeutics
NTLA
NTLA
319 hedge funds and large institutions have $3.81B invested in Intellia Therapeutics in 2022 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 114 increasing their positions, 96 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
11% more capital invested
Capital invested by funds: $3.42B → $3.81B (+$385M)
7% more funds holding
Funds holding: 299 → 319 (+20)
0.41% more ownership
Funds ownership: 89.13% → 89.54% (+0.41%)
Holders
319
Holding in Top 10
8
Calls
$48.5M
Puts
$38.2M
Top Buyers
| 1 | +$19.8M | |
| 2 | +$18.6M | |
| 3 | +$18.3M | |
| 4 |
Morgan Stanley
New York
|
+$18.3M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$17.9M |
Top Sellers
| 1 | -$42.1M | |
| 2 | -$28.3M | |
| 3 | -$28.3M | |
| 4 |
D.E. Shaw & Co
New York
|
-$23.2M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$21M |